Provided by Tiger Trade Technology Pte. Ltd.

Tonix Pharmaceuticals

12.38
-0.4500-3.51%
Volume:86.25K
Turnover:1.08M
Market Cap:212.33M
PE:-0.99
High:12.65
Open:12.52
Low:12.35
Close:12.83
52wk High:31.55
52wk Low:9.40
Shares:17.15M
Float Shares:14.99M
Volume Ratio:1.22
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.4882
EPS(LYR):-14.5713
ROE:-81.82%
ROA:-46.84%
PB:0.96
PE(LYR):-0.85

Loading ...

Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts

TIPRANKS
·
Jun 27

Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James

TIPRANKS
·
Jun 25

Tonix Pharmaceuticals publishes investor deck focused on TONMYA fibromyalgia launch and pipeline programs

Reuters
·
Jun 16

Tonix Pharma director Carolyn E. Taylor acquires 1,415 shares worth $14,928.25

Reuters
·
Jun 15

Tonix Pharma management to join BTIG Infectious Disease Day 1x1 meetings

Reuters
·
Jun 11

Tonix Pharma director Richard Newcomb Stillwell acquires 5,000 shares for $58,250

Reuters
·
Jun 10

Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage

MT Newswires Live
·
Jun 08

Tonix Pharmaceuticals secures second commercial agreement for Tonmya

TIPRANKS
·
Jun 08

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for Tonmya®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

THOMSON REUTERS
·
Jun 08

Tonix shares TNX-4800 Lyme disease prevention presentation

Reuters
·
Jun 01

Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch, pipeline updates

Reuters
·
Jun 01

Alliance Global Partners Sticks to Their Buy Rating for Tonix Pharma (TNXP)

TIPRANKS
·
Jun 01

Tonix presents real-world claims analysis showing persistent opioid prescribing in US fibromyalgia patients

Reuters
·
May 29

Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

GlobeNewswire
·
May 29

Tonix Pharmaceuticals publishes TNX-1500 data in Journal of Clinical Immunology

TIPRANKS
·
May 27

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

GlobeNewswire
·
May 27

Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Reuters
·
May 27

Analysts Offer Insights on Healthcare Companies: Daxor (DXR) and Tonix Pharma (TNXP)

TIPRANKS
·
May 26

Tonix Pharmaceuticals presents data from analysis of adults with fibromyalgia

TIPRANKS
·
May 26

Tonix presents real-world U.S. claims analysis of 261,776 fibromyalgia patients at ISPOR 2026

Reuters
·
May 26